share_log
  • Headlines
  • Zai Lab Reports Topline Data From Phase 3 Bridging Trial Evaluating KarXT For Schizophrenia In China; KarXT Demonstrated A Statistically Significant 9.2-Point Reduction In PANSS Total Score From Baseline At Week 5 Compared To Placebo, Trial Met All...

Zai Lab Reports Topline Data From Phase 3 Bridging Trial Evaluating KarXT For Schizophrenia In China; KarXT Demonstrated A Statistically Significant 9.2-Point Reduction In PANSS Total Score From Baseline At Week 5 Compared To Placebo, Trial Met All...

Benzinga ·  Oct 29 19:39

Zai Lab Reports Topline Data From Phase 3 Bridging Trial Evaluating KarXT For Schizophrenia In China; KarXT Demonstrated A Statistically Significant 9.2-Point Reduction In PANSS Total Score From Baseline At Week 5 Compared To Placebo, Trial Met All Secondary Endpoints

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated